Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Treasury Shares (2016 - 2025)

Fortress Biotech has reported Treasury Shares over the past 13 years, most recently at $3.8 million for Q4 2025.

  • For Q4 2025, Treasury Shares fell 12.98% year-over-year to $3.8 million; the TTM value through Dec 2025 reached $3.8 million, down 12.98%, while the annual FY2025 figure was $3.8 million, 12.98% down from the prior year.
  • Treasury Shares for Q1 2020 was $70000.0 at Fortress Biotech.
  • Over five years, Treasury Shares peaked at $23.0 million in Q1 2023 and troughed at $1.4 million in Q4 2022.
  • A 5-year average of $10.7 million and a median of $5.6 million in 2025 define the central range for Treasury Shares.
  • Biggest five-year swings in Treasury Shares: skyrocketed 368650.26% in 2021 and later plummeted 92.83% in 2023.
  • Year by year, Treasury Shares stood at $18.1 million in 2021, then crashed by 92.41% to $1.4 million in 2022, then surged by 50.86% to $2.1 million in 2023, then soared by 113.6% to $4.4 million in 2024, then dropped by 12.98% to $3.8 million in 2025.
  • Business Quant data shows Treasury Shares for FBIO at $3.8 million in Q4 2025, $5.1 million in Q3 2025, and $5.7 million in Q2 2025.